β Receptors: role in cardiometabolic disorders
Pharmacological and molecular approaches have shown that an atypical β-adrenoceptor (AR), called β 3 -AR, that is distinct from β 1 -ARs and β 2 -ARs, exists in some tissues in heterogeneous populations such as β 3a -ARs and β 3b -ARs. β 3 -ARs belong to a superfamily of receptors linked to guanine...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2011-04-01
|
| Series: | Therapeutic Advances in Endocrinology and Metabolism |
| Online Access: | https://doi.org/10.1177/2042018810390259 |
| Summary: | Pharmacological and molecular approaches have shown that an atypical β-adrenoceptor (AR), called β 3 -AR, that is distinct from β 1 -ARs and β 2 -ARs, exists in some tissues in heterogeneous populations such as β 3a -ARs and β 3b -ARs. β 3 -ARs belong to a superfamily of receptors linked to guanine nucleotide binding proteins (G proteins). The β 3 -AR gene contains two introns whereas the β 1 -AR and β 2 -AR genes are intronless, leading to splice variants. β 3 -ARs can couple to G i and G s and they are reported to be present in brown adipose tissue, vasculature, the heart, among other tissues. β 3 -ARs cause vasodilation of microvessels in the islets of Langerhans and may participate in the pathogenesis of cardiac failure, during which modification of β 1 -AR and β 2 -AR expression occurs. The development of β 3 -AR agonists has led to the elaboration of promising new drugs, including antiobesity and antidiabetic drugs. This article reviews the various pharmacological actions of β 3 -ARs and their clinical implications for diabetes and cardiovascular diseases. |
|---|---|
| ISSN: | 2042-0188 2042-0196 |